New medicines waited almost 2.5 years for reimbursement decisions, says IPHA

The 10 new innovative medicines recently approved by Ireland’s Health Service Executive for use by patients spent on average almost two-and-a-half years waiting for a reimbursement decision, according to the Irish Pharmaceutical Healthcare Association (IPHA), the body representing the research-based pharmaceutical industry.

The 10 products were approved for reimbursement over the coming months so it will be July before some of them will be available to Irish patients.

The products spent, on average, 890 days waiting for a reimbursement decision. The time-to-decision calculation is made from the point at which the products were licensed by the European Medicines Agency.